Age of onset and cumulative risk of mental disorders: a cross-national analysis of population surveys from 29 countries.
Adolescent
Humans
Male
Female
Young Adult
Adult
Depressive Disorder, Major
/ epidemiology
Age of Onset
Cross-Sectional Studies
Health Surveys
Mental Disorders
/ epidemiology
Phobic Disorders
/ epidemiology
Surveys and Questionnaires
Prevalence
Diagnostic and Statistical Manual of Mental Disorders
Comorbidity
Journal
The lancet. Psychiatry
ISSN: 2215-0374
Titre abrégé: Lancet Psychiatry
Pays: England
ID NLM: 101638123
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
20
03
2023
revised:
18
05
2023
accepted:
31
05
2023
pmc-release:
01
09
2024
medline:
21
8
2023
pubmed:
3
8
2023
entrez:
2
8
2023
Statut:
ppublish
Résumé
Information on the frequency and timing of mental disorder onsets across the lifespan is of fundamental importance for public health planning. Broad, cross-national estimates of this information from coordinated general population surveys were last updated in 2007. We aimed to provide updated and improved estimates of age-of-onset distributions, lifetime prevalence, and morbid risk. In this cross-national analysis, we analysed data from respondents aged 18 years or older to the World Mental Health surveys, a coordinated series of cross-sectional, face-to-face community epidemiological surveys administered between 2001 and 2022. In the surveys, the WHO Composite International Diagnostic Interview, a fully structured psychiatric diagnostic interview, was used to assess age of onset, lifetime prevalence, and morbid risk of 13 DSM-IV mental disorders until age 75 years across surveys by sex. We did not assess ethnicity. The surveys were geographically clustered and weighted to adjust for selection probability, and standard errors of incidence rates and cumulative incidence curves were calculated using the jackknife repeated replications simulation method, taking weighting and geographical clustering of data into account. We included 156 331 respondents from 32 surveys in 29 countries, including 12 low-income and middle-income countries and 17 high-income countries, and including 85 308 (54·5%) female respondents and 71 023 (45·4%) male respondents. The lifetime prevalence of any mental disorder was 28·6% (95% CI 27·9-29·2) for male respondents and 29·8% (29·2-30·3) for female respondents. Morbid risk of any mental disorder by age 75 years was 46·4% (44·9-47·8) for male respondents and 53·1% (51·9-54·3) for female respondents. Conditional probabilities of first onset peaked at approximately age 15 years, with a median age of onset of 19 years (IQR 14-32) for male respondents and 20 years (12-36) for female respondents. The two most prevalent disorders were alcohol use disorder and major depressive disorder for male respondents and major depressive disorder and specific phobia for female respondents. By age 75 years, approximately half the population can expect to develop one or more of the 13 mental disorders considered in this Article. These disorders typically first emerge in childhood, adolescence, or young adulthood. Services should have the capacity to detect and treat common mental disorders promptly and to optimise care that suits people at these crucial parts of the life course. None.
Sections du résumé
BACKGROUND
Information on the frequency and timing of mental disorder onsets across the lifespan is of fundamental importance for public health planning. Broad, cross-national estimates of this information from coordinated general population surveys were last updated in 2007. We aimed to provide updated and improved estimates of age-of-onset distributions, lifetime prevalence, and morbid risk.
METHODS
In this cross-national analysis, we analysed data from respondents aged 18 years or older to the World Mental Health surveys, a coordinated series of cross-sectional, face-to-face community epidemiological surveys administered between 2001 and 2022. In the surveys, the WHO Composite International Diagnostic Interview, a fully structured psychiatric diagnostic interview, was used to assess age of onset, lifetime prevalence, and morbid risk of 13 DSM-IV mental disorders until age 75 years across surveys by sex. We did not assess ethnicity. The surveys were geographically clustered and weighted to adjust for selection probability, and standard errors of incidence rates and cumulative incidence curves were calculated using the jackknife repeated replications simulation method, taking weighting and geographical clustering of data into account.
FINDINGS
We included 156 331 respondents from 32 surveys in 29 countries, including 12 low-income and middle-income countries and 17 high-income countries, and including 85 308 (54·5%) female respondents and 71 023 (45·4%) male respondents. The lifetime prevalence of any mental disorder was 28·6% (95% CI 27·9-29·2) for male respondents and 29·8% (29·2-30·3) for female respondents. Morbid risk of any mental disorder by age 75 years was 46·4% (44·9-47·8) for male respondents and 53·1% (51·9-54·3) for female respondents. Conditional probabilities of first onset peaked at approximately age 15 years, with a median age of onset of 19 years (IQR 14-32) for male respondents and 20 years (12-36) for female respondents. The two most prevalent disorders were alcohol use disorder and major depressive disorder for male respondents and major depressive disorder and specific phobia for female respondents.
INTERPRETATION
By age 75 years, approximately half the population can expect to develop one or more of the 13 mental disorders considered in this Article. These disorders typically first emerge in childhood, adolescence, or young adulthood. Services should have the capacity to detect and treat common mental disorders promptly and to optimise care that suits people at these crucial parts of the life course.
FUNDING
None.
Identifiants
pubmed: 37531964
pii: S2215-0366(23)00193-1
doi: 10.1016/S2215-0366(23)00193-1
pmc: PMC10529120
mid: NIHMS1923039
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
668-681Subventions
Organisme : NIDA NIH HHS
ID : R01 DA016558
Pays : United States
Organisme : FIC NIH HHS
ID : R03 TW006481
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH069864
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH061905
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH060220
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH070884
Pays : United States
Organisme : NIMH NIH HHS
ID : R13 MH066849
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH059575
Pays : United States
Organisme : NIMH NIH HHS
ID : U13 MH066849
Pays : United States
Investigateurs
Sergio Aguilar-Gaxiola
(S)
Ali Al-Hamzawi
(A)
Jordi Alonso
(J)
Yasmin A Altwaijri
(YA)
Laura Helena Andrade
(LH)
Lukoye Atwoli
(L)
Corina Benjet
(C)
Evelyn J Bromet
(EJ)
Ronny Bruffaerts
(R)
Brendan Bunting
(B)
José Miguel Caldas-de-Almeida
(JM)
Graça Cardoso
(G)
Stephanie Chardoul
(S)
Alfredo H Cía
(AH)
Louisa Degenhardt
(L)
Giovanni De Girolamo
(G)
Oye Gureje
(O)
Josep Maria Haro
(JM)
Meredith G Harris
(MG)
Hristo Hinkov
(H)
Chi-Yi Hu
(CY)
Peter De Jonge
(P)
Aimee N Karam
(AN)
Elie G Karam
(EG)
Georges Karam
(G)
Alan E Kazdin
(AE)
Norito Kawakami
(N)
Ronald C Kessler
(RC)
Andrzej Kiejna
(A)
Viviane Kovess-Masfety
(V)
John J McGrath
(JJ)
Maria Elena Medina-Mora
(ME)
Jacek Moskalewicz
(J)
Fernando Navarro-Mateu
(F)
Daisuke Nishi
(D)
Marina Piazza
(M)
José Posada-Villa
(J)
Kate M Scott
(KM)
Juan Carlos Stagnaro
(JC)
Dan J Stein
(DJ)
Margreet Ten Have
(M)
Yolanda Torres
(Y)
Maria Carmen Viana
(MC)
Daniel V Vigo
(DV)
Cristian Vladescu
(C)
David R Williams
(DR)
Peter Woodruff
(P)
Bogdan Wojtyniak
(B)
Miguel Xavier
(M)
Alan M Zaslavsky
(AM)
Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests LD receives educational grants from Indivior and Seqirus. OVD receives funding from Kowa Research Institute and has been an advisor in the PROMINENT trial. SMK and PWW receive grant funding from Hamad Medical Corporation through the Cambridgeshire and Peterborough National Health Service Foundation trust and from Qatar University. PWW has received financial support from the Qatar National Research Fund and an honorarium from Gresham College. RCK has been a consultant for Cambridge Health Alliance, Canandaigua Veterans Affairs Medical Center, Holmusk, Partners Healthcare, RallyPoint Networks, and Sage Therapeutics. He holds stock options in Cerebral, Mirah, Prepare Your Mind, Roga Sciences, and Verisense Health. DN receives honoraria from AIG General Insurance and Takeda Pharmaceutical and financial support from Startia, En-power, and MD.net. DJS receives royalties from American Psychiatric Press, Cambridge University Press, and Elsevier–Academic Press. He has received honoraria from Discovery Vitality, Johnson & Johnson, Kanna, L'Oreal, Lundbeck, Orion, Sanofi, Servier, Takeda, and Vistagen. He was the president of the African College of Neuropsychopharmacology and is financially supported by the Medical Research Council of South Africa. All other authors declare no competing interests.
Références
World Psychiatry. 2020 Oct;19(3):339-349
pubmed: 32931098
World Psychiatry. 2007 Oct;6(3):168-76
pubmed: 18188442
Lancet Psychiatry. 2021 Apr;8(4):310-319
pubmed: 33743882
J Health Soc Behav. 1981 Mar;22(1):49-64
pubmed: 7240706
World Psychiatry. 2007 Oct;6(3):177-85
pubmed: 18188443
JAMA Psychiatry. 2015 Apr;72(4):334-41
pubmed: 25671328
Lancet Psychiatry. 2017 Jan;4(1):8-9
pubmed: 27856397
Eur J Epidemiol. 2022 Feb;37(2):173-194
pubmed: 34978669
Mol Psychiatry. 2022 Jan;27(1):281-295
pubmed: 34079068
JAMA Psychiatry. 2021 Jul 1;78(7):735-743
pubmed: 33881469
Psychol Med. 2010 Jun;40(6):899-909
pubmed: 19719899
Med J Aust. 2007 Oct 1;187(S7):S40-2
pubmed: 17908024
Int J Methods Psychiatr Res. 2006;15(4):167-80
pubmed: 17266013
Scand J Public Health. 2008 Sep;36(7):728-36
pubmed: 18647788
JAMA Psychiatry. 2019 Mar 1;76(3):259-270
pubmed: 30649197
Am J Hum Genet. 2022 Mar 3;109(3):417-432
pubmed: 35139346
Acta Psychiatr Scand. 2022 Jun;145(6):604-614
pubmed: 35152414
Epidemiol Psychiatr Sci. 2020 Aug 12;29:e153
pubmed: 32782057